<DOC>
	<DOC>NCT01131585</DOC>
	<brief_summary>This study was designed to confirm the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in patients with visual impairment due to Diabetic Macular Edema. A subgroup of patients with Proliferative Diabetic Retinopathy were included to evaluate the efficacy and safety of laser photocoagulation as adjunctive therapy to ranibizumab 0.5 mg versus laser monotherapy in this population.</brief_summary>
	<brief_title>Safety and Efficacy of Ranibizumab in Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Visual acuity impairment caused by macular edema in at least one eye Type 1 or type 2 diabetes mellitus Stable medication of diabetes in past 3 month Patients with uncontrolled systemic or ocular diseases Laser photocoagulation in the study eye for the last 3 months Any history of any intraocular surgery in the study eye within the past 3 months Blood pressure &gt; 160/100 mmHg Other protocol defined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Diabetic macular edema</keyword>
	<keyword>DME</keyword>
	<keyword>Proliferative diabetic retinopathy</keyword>
	<keyword>PDR</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>laser</keyword>
</DOC>